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Received November 10, 2014; accepted December 31, 2014AbstractThe epithelialemesenchymal transition (EMT) process plays pivotal roles in regulatory mechanisms of embryogenesis and wound healing
physiologically, and organ fibrosis, cancer progression, and metastasis pathologically. EMT is classified as primary, secondary, and tertiary
during embryonic development. EMT contributes to repair of tissue injury and fibrogenesis by re-epithelialization and regeneration of fibro-
blasts, respectively. The hallmarks of EMT include loss of contact inhibition, remodeling of extracellular matrix, and reorganization of cyto-
skeleton, along with expression of mesenchymal markers and reduction of epithelial markers. Cancer cells acquire stemness, migration and
invasive capability, evade apoptosis, and initiate metastasis to distant organs. Several EMT regulators including Snail, Zeb1, Zeb2, and Twist in
solid tumor and Sox4, distal-less homeobox gene 4 (DLX4), Prdm14, Bmi1, and the forkhead box family in hematological malignancy are
reviewed with regard to their signaling pathways, regulatory mechanisms, and clinical interactions.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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The epithelialemesenchymal transition (EMT) is the pro-
cess of conversion of cells from a differentiated epithelial state
into a dedifferentiated migratory mesenchymal phenotype,
which is crucial for regulatory mechanisms in embryogenesis,
cancer metastasis, organ fibrosis, and wound healing.1
2. Physiologic EMT
During embryogenesis, EMT is classified as primary, sec-
ondary, and tertiary.2 In the process of primary EMT, the firstConflicts of interest: The authors declare that there are no conflicts of interest
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical AssEMT incident in the embryo occurs during gastrulation when
cells from the epiblast move to a primitive streak in the
midline and undergo EMT to form the mesoderm and the
ectoderm.3 Another primary EMT process occurs during the
generation of neural crest cells, when epithelial cells become
neural crest cells and migrate to form neural tubes, which
develops into the central nervous system in mammals.4
During embryogenesis, transient epithelial structures
including the notochord, somites, somatopleures, and
splanchnopleures also undergo secondary EMT to generate
mesenchymal cells, which subsequently differentiate into
specific cell types, such as those of connective tissue, he-
matopoietic stem cells, endocardium, muscle, and neural
arches. The mesenchyme of liver and islets of Langerhans also
develop through secondary EMT from the liver diverticulum
and pancreatic bud, respectively.5,6 The physiologic event
involving tertiary EMT is the formation of mesenchymal
cardiac jelly from endothelial cells located in theociation. All rights reserved.
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becomes the endocardial cushion.7
In addition to embryogenesis, EMT also participates in the
physiologic repair of tissue injury, that is, the re-
epithelialization of wounds. Keratinocytes assembling
around the border of a wound will undergo phenotypic con-
version to an intermediate “metastable” phenotype and then
acquire mesenchymal characteristics including loss of
cellecell adherence and polarity, and gain in migratory ac-
tivity.8 The ovarian epithelial cells also utilize EMT to assume
a fibroblast-like phenotype in the postovulatory phase and
reside in the ovary mesenchyme, which promotes tissue repair
in response to ovulation.9
3. Pathologic EMT
During renal fibrogenesis, interstitial fibroblast can origi-
nate from progenitors of tissue fibroblasts (bone marrow
derived) migrating in the circulation to repopulate in periph-
eral organs; however, they also can originate de novo from the
epithelium through the EMT process to generate a much larger
number of fibroblasts.10 It is not a unique process for renal
fibrogenesis, and hepatocytes, lens epithelium, endothelium,
and cardiomyocytes can contribute to tissue fibrosis in a
similar manner. In a murine animal model, hepatocytes
derived from cirrhotic liver demonstrated features of EMT
including mitogen-activated protein kinase-dependent
increased expression of vimentin and type I collagen, sug-
gesting the involvement of EMT in the mechanism of hepa-
tocellular carcinoma genesis.11 Cardiac fibrosis was associated
with the recruitment of fibroblasts from endothelial cells un-
dergoing EMT.12 For patients receiving peritoneal dialysis,
mesothelial cells go through EMT to transform into cells with
epithelioid morphology, resulting in peritoneal fibrosis, and
eventually, dysfunction of the peritoneal membrane.13
4. EMT in solid tumors
Accumulated evidence suggests that EMT plays pivotal
roles in cancer progression and metastasis, but the effects of
EMT on human tumors remain inconclusive.14,15 Cancer cells
acquire their stem cell-like property, that is, the capability of
metastatic colonization and resistance to treatment, through
the process of EMT to promote deposition of extracellular
matrix.2
In the invasive front of tumor of colon carcinoma, migra-
tory tumor cells at the edge will display morphological fea-
tures of EMT, including loss of E-cadherin and basement
membrane.16 Similar phenomena were also observed in
papillary thyroid carcinoma, in which EMT was associated
with tumor invasion and nodal metastasis.17
Several hallmark processes are crucial in EMT, including
loss of E-cadherin and polarity but increase of N-cadherin and
vimentin. Upon initiation of EMT, loss of E-cadherin pro-
motes invasion during carcinoma progression and E-cadherin
is repressed by EMT-related factors either directly or indi-
rectly. Snail, Zeb, E47, and KLF8 directly bind to thepromoter of CDH1, which encodes E-cadherin and down-
regulates the expression of E-cadherin,18,19 whereas Twist,
goosecoid, E2-2A, E2-2B, and FoxC2 indirectly transcrip-
tionally inhibit E-cadherin.20,21
5. Direct regulators of EMT5.1. SnailSnail is of enormous significance in physiologic EMT, such
as in gastrulation and formation of neural crest. Snail1 is one
of the repressive transcription factors directly binding to the
promoter of CDH1. In breast carcinoma, the expression of
Snail1 was associated with repression of E-cadherin and
lymph node metastasis.22
Snail1 interacts with Suz12 and Ezh2 and recruits poly-
comb complex 2 to repress CDH1.23 Snail1 binds to the E2-
box [C/A(CAGGTG)] on the promoter with its C-terminal
domain or interacts with histone deacetylases with its SNAG
sequence in the N-terminal domain.24,25 The translation of
Snail1 messenger RNA (mRNA) can be activated by Y box
binding protein 1 in breast carcinoma,26 and its nuclear
localization is promoted by LIV1, which is a downstream
signaling target of signal transducer and activator of tran-
scription 3.27 Many post-translational modifications have been
found, such as the p21-activated kinase 1 regulating the level
of subcellular localization by phosphorylation of Snail28 and
glycogen synthesis kinase 3b (GSK3b)-mediated phosphory-
lation facilitating the ubiquitin-dependent degradation of
Snail.29 By contrast, Lox2 counteracts GSK3b and stabilizes
Snail.30 The cooperative corepressors may be required for
Snail to function; for example, these corepressors are required
for the SMAD protein to bind to Snail to form a repressive
complex inhibiting transforming growth factor-b (TGF-b)-
induced EMT.315.2. Zeb1The expression of Zeb1 can be induced by Snail1,32 but its
function is independent of Snail because it is associated with
repression of CDH1 in the absence of Snail in colon carci-
noma, which implies that the inducers of EMT are dependent
on the cellular context.335.3. TwistTwist belongs to the category of basic helixeloopehelix
factor transcription factors. Besides being a master regulator
of embryogenesis, Twist also induces EMT and metastasis and
is associated with poor survival in invasive breast ductal car-
cinoma, endometrial cancer, hepatocellular cancer, and mel-
anomas.34e37 Downstream targets of Twist include platelet-
derived growth factor receptor-a, Akt2, Snail1, and Snail2.
Twist is upregulated by nuclear factor-kB (NF-kB), hypoxia-
inducible factor 1-a, and SRC-1/PEA3.38e42 Twist represses
E-cadherin and upregulates N-cadherin and vimentin, which
are the hallmarks of EMT.
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In phyllodes tumor, methylation of the promoters of Twist1
was noted in approximately 10.7% of tumor samples, which
correlated with more high-grade malignancy.44 In breast car-
cinoma, Twist is overexpressed in all high-grade tumors and
represses the expression of estrogen receptor (ER) by
recruiting DNA methyltransferase to the ER promoter and by
interacting with histone deacetyltransferase 1.45 Twist1 and
Bmi1 are mutually essential for promoting EMT and tumor-
initiating capability in head and neck squamous cell carci-
noma, which implies that chromatin remodeling was crucial in
the mechanisms of Twist-induced EMT.46 Twist1 also binds to
the Twist box in the C-terminus of p53 to counteract the post-
translational modifications of p53 and facilitates its degrada-
tion mediated by mouse double minute 2 homolog protein
(MDM2).47 Overexpression of Twist transforms breast cancer
cells into cancer stem cell phenotypes with characteristics of
high CD44 expression, no or little CD24 expression, and
increased aldehyde dehydrogenase 1 activity independent of
the mechanisms of EMT.48 By contrast, activation of b-catenin
and Akt pathways is required for overexpressing Twist to
maintain the EMT-associated cancer stem cells of breast car-
cinoma and cervical carcinoma.49
Twist overexpression contributes to cisplatin and anthra-
cycline resistance in bladder cancer cells,50 and development
of multidrug resistance might be explained by increase of
Twist expression and adenosine triphosphate-binding cassette
transporters.51
6. EMT in hematological malignancy
Although leukemia or lymphoma cells of hematological
malignancy are embryonically developed from the mesoderm,
the so-called EMT, or mesenchymaleepithelial transition
(MET), was rarely reported in previous studies. However,
because EMT-related factors are associated with invasiveness,
migration capability, stemness, and drug resistance, EMT is a
crucial mechanism for cancer cells during disease progression.
Even for normal physiologic development of blood cells,
EMT-related factors may also play pivotal roles. For example,
extracellular signal-regulated kinase-mediated phosphoryla-
tion of E2A, which is also directly related to EMT, controls its
degradation in response to Notch signaling during lymphocyte
differentiation.52 E2A gene products (E12 and E47) are also
targets for G1 cyclin-dependent kinases regulating B-cell
growth and survival during development.53 Twist over-
expression is associated with the resistance to imatinib in
chronic myeloid leukemia cases; in addition, Twist expression
is repressed by tyrosine kinase inhibitors but is upregulated
when the resistance develops.54
7. Factors related to cell cycle control or DNA repair7.1. Sox4Sex-determining region Y-related high-mobility-group-box
transcription factors belong to a large family composed ofeight groups from A to H in vertebrates.55 Sox4 regulates
embryogenesis and mesenchymal differentiation.56 Knockout
of Sox4 leads to the arrest of B-cell development at the pro-B-
cell stage and impaired TGF-b-mediated T-helper type 2 cell
differentiation.57,58 In adults, Sox4 expression is distributed in
the tissues of pancreatic islets cells, gonads, thymus, and he-
matopoietic stem cells.59,60 Sox4 has been identified as the
most common integration site for retrovirus in leukemia and
lymphomas, suggesting that Sox4 plays roles in inducing he-
matologic malignancy such as mouse myeloid leukemia and
splenic marginal zone lymphoma.61,62 The expression of Sox4
correlates with the cyclic adenosine monophosphate response
element-binding protein expression in patients with acute
myeloid leukemia (AML), both of which coexist to promote
proliferation of hematopoietic progenitors.63 Both Sox4 and
PBX1 are well-known important hematopoietic stem cell
regulators.64 However, the detailed mechanisms involving
Sox4 in generation of leukemic cells remain unresolved. In
addition, Sox4 also binds to the promoter of CD56 in myeloma
cells and is associated with lytic bone lesions and worse sur-
vival.64 Sox4 is also involved in EMT in hepatocellular car-
cinoma or mammary epithelial cells and in increased
stemness, inducing migration capability, and metastasis and
invasiveness, which might be regulated by TGF-b.65 Sox4 also
acts cooperatively with Oct4 to bind to the Sox2 promoter,
contributing to the stemness of glioma-initiating cells and
disease progression.66 However, besides its role in EMT, Sox4
has also been identified as a tumor suppressor because it in-
terplays with p53 in the DNA repair pathway involving acti-
vation of ataxia telangiectasia mutated/ataxia telangiectasia
and Rad3-related kinases in medulloblastoma.677.2. Bmi1B-cell-specific Moloney murine leukemia virus integration
site 1 (Bmi1) is a member of polycomb repressive complex 1,
which plays a pivotal role in self-renewal of cancer stem cells,
which explains tumor recurrence and resistance to chemo-
therapeutic drugs in melanoma, neuroblastoma, and oropha-
ryngeal squamous cell carcinoma.68 Bmi1 is located on
10p11.23 and universally expressed in all human tissues over
the body.69 Increased expression of Bmi1 is specifically found
in hematopoietic and neural stem cells because it inhibits
senescence and maintains immortality of cells by activating
telomerase.68,70
It is co-expressed with other cancer stem cell markers in
lymphoma.71 Bmi1 promotes the proliferation of leukemia
stem cells and normal hematopoietic stem cells72 by abolish-
ing the p16INK4A/RB and p53/MDM2 pathways to prevent
cell arrest.73 Bmi1 acts synergistically with Twist to induce
EMT in head and neck squamous carcinoma, and therefore,
increased expression of Bmi1 is correlated with worst prog-
nosis.46 In addition to EMT and stemness, Bmi1 is also
associated with chemoresistance. In studies of ovarian carci-
noma, prostate cancer, and pancreatic cancer, Bmi1 increased
resistance to chemotherapeutic drugs including cisplatin,
paclitaxel, docetaxel, and gemcitabine, respectively, by
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to be related to reactive oxygen species.74 Bmi1 also activates
NF-kB, rendering glioma cells antiapoptic and resistant to
chemotherapy and radiotherapy.75 In nasopharyngeal carci-
noma, upregulation of Bmi1 stabilized Snail and repressed
PTEN, i.e. phosphatase and tensin homolog, which was
identified as a tumor suppressor in a large body of cancers,
whereas the abrogating PTEN reversed EMT-associated in-
vasion and migration.76 Bmi also promoted proliferation of
keratinocyte by upregulating the expression of cyclin-
dependent kinase 2 and 4, and cyclin D1, whereas it inhibi-
ted the activity of caspase and poly-adenosine diphosphate-
ribose polymerase cleavage.77 Bmi1 was involved in the dif-
ferentiation of helper T cells (Th2) through stabilization of
GATA-binding protein 3.787.3. Forkhead boxForkhead box (Fox) proteins are among a large family of
transcription factors regulating cell growth, differentiation,
and embryogenesis of the mesoderm.79 The Fox family shares
a conserved Fox domain also known as “Winged-helix
domain,” which is involved in DNA binding, and another
extra-Fox proteineprotein interaction domain, which is
involved in interactions with other transcription factors or
DNA repair complexes.80 As the Fox family contains more
than 30 factors, it is beyond the scope of this review to detail
all the factors; instead, we only focus on factors with regard to
EMT and hematologic malignancy.
FOXM1 oncogene, located at chromosome 12p13.33, was
found to be amplified in 42% of non-Hodgkin's lymphoma,
including diffuse large B-cell lymphoma, follicular lymphoma,
and B-cell chronic lymphocytic leukemia, and associated with
increased expression of Myc.81 Unphosphorylated FOXM1
located in the cytoplasm at the G1/S phase will be transported
to the nucleus after phosphorylation by MEK1 at the G2/M
phase, and abolishment of MEK1 will lead to repression of
FOXM1 and delayed cell cycle in the G2/M phase.
82,83 In
pancreatic cancer overexpressing FOXM1, activation of EMT
regulators including Zeb1, Zeb2, and Snail2 was noted along
with downregulation of microRNAs (miRNAs; let-7a, let-7b,
let-7c, miR-200b, and miR-200c).84 FOXM1 regulates cell
cycle control through centromere protein A, centromere pro-
tein B, cell division cycle 25B, aurora B kinase, survivin,
Skp2, and Cks1 and angiogenesis through matrix metal-
loproteinases and vascular endothelial growth factor.83,85,86
Chromosomal translocations leading to fusion of Foxp1 and
immunoglobulin heavy-chain locus [t(3;14)] or amplifications
of Foxp1 were frequently noted in mucosa-associated
lymphoid tissue (MALT) lymphoma and diffuse large B-cell
lymphoma but these are not responsible for the overexpression
of Foxp1.87,88 However, high expression of Foxp1 was asso-
ciated with nongerminal center, activated B-cell-type diffuse
large B-cell lymphoma as well as with extremely poor prog-
nosis.89 Similarly, high expression of Foxp1 and stages were
both significant prognostic factors for gastric MALT lym-
phoma.90 Foxp1 is essential for B lymphocyte differentiationin both transition from pro-B to pre-B cell stage and control of
variable-joining recombination of genes encoding immuno-
globulin heavy chain.91 High expression of Foxc2 was asso-
ciated with basal-like breast cancer and several EMT-related
factors including Snail, Twist, goosecoid, Zeb1, Zeb2, and Ets-
1 enhance the ability of metastasis.92,93
8. Factors related to epigenetic modulation or
pluripotency8.1. Prdm14Prdm14 is a transcription factor of the PR domain-
containing large family, which is suggested to have histone
methyltransferase activity.94 Prdm14 is normally expressed
specifically in pluripotent cells and it functions as repressors
of differentiation in embryonic stem cells to maintain the
renewal of stem cells.95 Prdm14 can cooperatively act with
Oct4, Sox2, and Klf to regulate the reprogramming of human
fibroblasts and the expression of POU5F1, which is a gene of
pluripotency.96 Prdm14 is also expressed in 25% of lymphoid
leukemia, which can block B-cell differentiation at the pro-B-
cell stage. In common lymphoid progenitors transduced with
Prdm14, genes associated with pluripotency, EMT, tumor
formation, Wnt/Ras signaling, and early B-cell commitment
were upregulated.978.2. Distal-less homeobox gene 4 (DLX4)Distal-less homeobox gene 4, DLX4, putatively termed as
“beta protein 1” is a member of the DLX4 family, and performs
the functions of repressing the expression of beta-globin in
early erythroid cells and controlling bone morphogenesis and
skeletal patterning.98 However, aberrantly high expression of
DLX4 mRNAwas found in 63% of AML blasts and in 32% of
T-cell acute lymphoblastic leukemia but not in B-lineage acute
leukemia. Besides its expression in leukemia blasts, expression
of DLX4 is noted only in CD34-negative cells in normal bone
marrow.99 DLX4 can induce EMT and promote migration and
invasiveness of breast cancer cells by upregulating Twist.100
9. Future perspectives
EMT-related factors are crucial for normal physiologic
development and pathologic cancerous progression. Whereas
carcinoma cells utilize the reprogramming process of EMT to
acquire their stemness, migratory, invasive, and metastatic
abilities, cancers of mesenchymal origin such as leukemia and
lymphoma seem to derive their chemoresistance or their
ability to evade key driver signaling pathways through other
functions of EMT-related factors (Figure 1). On the other side,
MET is another subject of investigation field, which seems not
just a reversal of EMT but an entirely divergent process.
Because these regulators of EMT program are transcription
factors, cancer therapeutics targeting them are very difficult to
achieve. Although some in vivo and vitro studies utilized RNA
interference specific to the EMT regulators to intervene in the
Figure 1. Connecting signaling pathways to epithelialemesenchymal transition (EMT)-related transcriptions factors. Snail and Twist inhibit epithelial marker (E-
cadherin) but promote mesenchymal marker (vimentin), both of which are hallmarks of EMT. Snail is induced by transforming growth factor-b (TGF-b) directly or
by Bmi1 through the phosphatase and tensin homolog/phosphoinositide 3-kinase (PI3K)/Akt pathway, but is inhibited by glycogen synthase kinase-3b (GSK3b)-
mediated phosphorylation. In addition to direct promotion of EMT, Twist acts synergistically with Bmi1 or enhances EMT thorough FoxC2. Bmi1 also regulates
cell cycle control through cyclin and cyclin-dependent kinase 4 and 6 (CDK-4,6) as well as through DNA repair mechanisms, such as p53 and p21. The regulation
of cell cycle control by FOXM1 is associated with centromere protein A (CENPA), centromere protein B (CENPB), cell division cycle 25B (CDC25B), and aurora
kinases B (AURKB). Overexpression of Prdm14 is associated with EMT and retinol binding protein 1 (Rbp1), SEC14 and spectrin domain 1 (Sestd1), scinderin
(Scin), CD248, and angiomotin like 1 (Amotl1). Fox ¼ forkhead box; HIF ¼ hypoxia-inducible factor.
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conferring more stability and specificity of miRNA, which is
tolerated more by immune surveillance of hosts, are war-
ranted. In addition to inhibiting positive regulators of the EMT
program, augmentation of negative transcription factors might
be an alternative to revert it, such as KLF17 or DEAR1 in
breast cancer. Other strategies to target TGF-b, the Hedgehog/
Snail pathway, Notch, or Wnt/b-catenin pathways by antibody
or small-molecule tyrosine kinase inhibitors are currently
under development. Alternative approaches are developing
drugs targeting cancer stem cells or circulating tumor cells
featuring upregulation of EMT factors, such as salinomycin,
although this concept remains preliminary currently.
Many EMT regulators have been reported to be prognos-
tically significant in numerous studies. Nonetheless, their role
as predictive factors are lacking, as cancer therapeutics tar-
geting them are still in trial. Detecting the dedifferentiated
circulating tumor cells with overexpression of Twist, Bmi1,
and other markers of EMT provides some hope to predict risk
of distant metastasis in early breast cancer.
EMT involves an extremely large network of transcription
factors, such as Snail, Twist, Zeb1, Zeb2, Bmi1, Sox4, DLX4,
Prdm14, Bmi1, and Fox family, in a cellular context-
dependent manner. It is fundamental to delineate the mecha-
nisms of EMT to understand cancer progression and metas-
tasis and, more importantly, to develop drugs targeting thesepathways. Appreciating these factors provides a rationale and
standpoint for targeted therapeutic agents and helps to prog-
nostically stratify patients into different subgroups that share
different survivals and possibly individualized treatments.
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